ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Geographic equity in oncology clinical trials in Spain: fragmentation, indicators, and evidence.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spain is one of Europe's leading countries in oncology clinical research by trial volume, with sustained growth in trial activity. However, the geography of innovation is not necessarily the geography of need. Using publicly reproducible indicators, we describe pronounced territorial concentration in oncology clinical research activity across Spain's autonomous communities (CCAA) and discuss the implications for equity of access to therapeutic innovation. Two complementary measures were juxtaposed: (i) REec-derived onco-hematology medication trial presence by CCAA in 2022 (reflecting where trials are activated), and (ii) population-normalized oncology trial participations per 100,000 inhabitants in 2016-2020 derived from AECC reporting (reflecting realized access to enrollment over time). Both indicators converge on a consistent pattern: trial activity and participation are concentrated in a small number of CCAA. Madrid and Catalonia together account for 41.4% of trial presences in 2022 (640 of 1546), and population-normalized participation ranged from 0.2 to 41.9 per 100,000 inhabitants across regions. When viewed alongside regional incidence and mortality patterns and contemporary mortality trends, research intensity does not appear to align consistently with cancer burden, suggesting that historical infrastructure, administrative capacity, and trial hub effects may be stronger determinants than epidemiological need. These findings support a shift from ad hoc assessments to routine monitoring of research equity, leveraging REec and existing national cancer-indicator platforms, alongside targeted capacity-building and networked collaboration to ensure that access to clinical research is not determined by place of residence.
Indexed as
Identifiers
42228281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.